Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92792 citas

 
 
 1 a 20 de 356 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Tracy DK. Gabapentinoids linked to new risks, including suicidal behaviour. BMJ 2019;365:12 de junio. [Ref.ID 103153]
3. Cita con resumen
Randolph AC, Lin Y-L, Volpi E, Kuo Y-F. Tricyclic antidepressant and/or ?-aminobutyric acid–analog use is associated with fall risk in diabetic peripheral neuropathy. J Am Geriatr Soc 2019;67:junio. [Ref.ID 103149]
4.Enlace a cita original Cita con resumen
Finnerub NB. Nonnarcotic methods of pain management. N Engl J Med 2019;380:20 de junio. [Ref.ID 103139]
5.Enlace a cita original Cita con resumen
Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]
6.Enlace a cita original Cita con resumen
7.Enlace a cita original Cita con resumen
Goodman CW, Brett AS. A clinical overview of off-label use of gabapentinoid drugs. JAMA Intern Med 2019;179:mayo. [Ref.ID 103073]
8.Enlace a cita original Cita con resumen
Brutcher RE, Kurihara C, Bicket MC, Moussavian-Yousef P, Reece DE, Solomon LM, Griffith SR, Jamison DE, Cohen SP. Compounded topical pain creams to treat localized chronic pain: a randomized controlled trial. Ann Intern Med 2019;170:mayo. [Ref.ID 103014]
9. Cita con resumen
Montastruc F, Loo SY, Renoux C. Trends in first gabapentin and pregabalin prescriptions in primary care in the United Kingdom, 1993-2017. JAMA 2018;320:27 de noviembre. [Ref.ID 102915]
10. Cita con resumen
Ortiz de Landaluce L, Carbonell P, Asensio C, Escoda N, López P, Laporte JR. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf 2018;41:diciembre. [Ref.ID 102913]
11.Enlace a cita original Cita con resumen
Mayor S. Pregabalin and gabapentin become controlled drugs to cut deaths from misuse. BMJ 2018;363:16 de octubre. [Ref.ID 102878]
12.Enlace a cita original Cita con resumen
Robertson K, Marshman LAG, Plummer D, Downs E. Effect of gabapentin vs pregabalin on pain intensity in adults ith chronic sciatica: a randomized clinical trial. JAMA Neurology 2018:15 de octubre. [Ref.ID 102863]
13. Cita con resumen
King MA. Pregabalin and gabapentin associated with depression and suicidal ideation. BMJ 2018;363:29 de noviembre. [Ref.ID 102862]
14.Enlace a cita originalTiene citas relacionadas Cita con resumen
Wallach JD, Ross JS. Gabapentin approvals, off-label use, and lessons for postmarketing evaluation efforts. JAMA 2018;319:27 de febrero. [Ref.ID 102781]
15.Enlace a cita original Cita con resumen
Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]
16.Enlace a cita originalTiene citas relacionadas Cita con resumen
Moore A, Derry S, Wiffen P. Gabapentin for chronic neuropathic pain. JAMA 2018;319:27 de febrero. [Ref.ID 102777]
17. Cita con resumen
Enke O, New HA, New CH, Mathieson S, McLachlan AJ, Latimer J, Maher CG, Lin CC. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. Can Med Assoc J 2018;190:E786-93. [Ref.ID 102754]
19.Enlace a cita original Cita con resumen
Throckmorton DC, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse — Proactive pharmacovigilance. N Engl J Med 2018;379:19 de julio. [Ref.ID 102679]
Seleccionar todas
 
 1 a 20 de 356 siguiente >>